Inhibikase Therapeutics, Inc. (NASDAQ:IKT) Q2 2024 Earnings Call Transcript
Inhibikase Therapeutics, Inc.
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Soleus Capital Guy Levy | 10,875,000 | $22,076,250 | 0.76% | |
| 2. | Trails Edge Capital Partners Ortav (Tavi) Yehudai | 9,051,318 | $18,374,176 | +13% | 2.92% |
| 3. | ADAR1 Capital Management Daniel Schneeberger | 7,387,205 | $14,996,026 | +12% | 0.69% |
| 4. | Siren L.L.C. Raymond Debbane | 5,850,000 | $11,875,500 | 0.24% | |
| 5. | Commodore Capital Egen Atkinson And Michael Kramarz | 5,397,488 | $10,956,901 | 0.65% |
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $1.45 | 2,068,965 | $2,999,999.25 | 13,018,965 | 2025-11-21 | Filing | |
| $1.37 | 1,460,000 | $2,000,200.00 | 1,460,000 | 2024-10-21 | Filing | |
| $1.37 | 145,000 | $198,650.00 | 145,000 | 2024-10-21 | Filing | |
| $1.37 | 365,000 | $500,050.00 | 365,000 | 2024-10-21 | Filing | |
| $0.80 | 5,000 | $4,000.00 | 5,335,433 | 2022-08-16 | Filing |
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 13,018,965 | $26,428,499 | 4.31% | |
| 2. | 8,625,000 | $17,508,750 | 1.16% | |
| 3. | 7,768,057 | $15,769,155 | 0% | |
| 4. | 5,938,276 | $12,054,700 | 0.04% | |
| 5. | 4,935,354 | $10,018,769 | 0% |